SCHEMBL4469737

SCHEMBL4469737

COc1ccc(N2CC3(CCC3)Cc3cc(O)c(C)c(C)c32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ALDH1A1 P00352 4/20 0.33
HTR1A P08908 2/20 0.33
CYP3A4 P08684 6/20 0.33
ATM Q13315 1/20 0.32
USP2 O75604 3/20 0.32
MEN1 O00255 2/20 0.32
CYP2C9 P11712 2/20 0.32
KMT2A Q03164 2/20 0.32
CYP1A2 P05177 2/20 0.32
HIF1A Q16665 2/20 0.32
HSD17B10 Q99714 1/20 0.32
CYP2C19 P33261 3/20 0.32
MAPK1 P28482 1/20 0.32
NPC1 O15118 2/20 0.32
PKM P14618 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4473362 0.88
SCHEMBL4472455 0.86 SPR (0.34) LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL4464111 0.86 SSTR5 (0.35)
SCHEMBL4472622 0.83 SSTR5 (0.39) MAPTTDP1ALDH1A1MEN1KMT2A
SCHEMBL13763087 0.82 ALDH1A1 (0.39) LMNAMAPTALDH1A1MAPK1NPC1
SCHEMBL4467896 0.82 KCNJ1 (0.39)
SCHEMBL4484839 0.80 MEN1 (0.34) MAPTALDH1A1MEN1KMT2AHSD17B10
SCHEMBL4463115 0.77 CYP11B2 (0.34) CYP3A4
SCHEMBL4468208 0.77 HSP90AA1 (0.35) HSD17B3
SCHEMBL4463874 0.76 KMT2A (0.42) LMNAMAPTTDP1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US claimed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 LMNA 1769/4885MAPT 4822/4885HTT 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.